Aluminium adjuvants (preservatives) in vaccines are commonly blamed, at least in part, for the increase in autism. Recent work has been done that confirms this theory, so I asked the TGA about the subject. Research on aluminium was conducted on aluminium salts, but the jabs use a quite different type of aluminium which has not been safety tested. This is my exact question:

“A study published in September took biopsies from the brains of older children diagnosed with autism and found their brains contained significantly elevated levels of aluminium, especially aluminium hydroxide and aluminium phosphate, which are present in the hexa jabs. Has the health testing on aluminium build-up in our children’s bodies been done using water-soluble aluminium salts, which are not used in vaccine products, or has this research been done using the actual aluminium used in vaccine products, aluminium hydroxide and aluminium phosphate?”

This question was straightforward and simply put: have you tested the right type of aluminium for safety? The TGA feigned not understanding the question to avoid answering it. When pressed, they took the question on notice and then refused to provide further information, with Minister Gallagher covering for her bureaucrats. This is unbecoming for a senior bureaucrat and for the Minister.

Australians want an answer to this, and I will keep at the subject until I get one. The fact they are hiding from the question suggests the answer is as recent science is showing – aluminium preservatives in vaccines are causing autism in some children.

Transcript

Senator ROBERTS: My third and final set of questions is about aluminium adjuvants. Again, constituents are raising this. A study published in September took biopsies from the brains of older children diagnosed with
autism and found their brains contained significantly elevated levels of aluminium, especially aluminium hydroxide and aluminium phosphate, which are present in the hexa jabs. Has the health testing on aluminium
build-up in our children’s bodies been done using water-soluble aluminium salts, which are not used in vaccine products, or has this research been done using the actual aluminium used in vaccine products, aluminium
hydroxide and aluminium phosphate?

Prof. Lawler: Sorry; did you reference research? There was a question there about whether research has been done?

Senator ROBERTS: Has the research been done on babies’ brains using the aluminium found in vaccine products, aluminium hydroxide and aluminium phosphate, or has it been done using water-soluble aluminium
salts?

Prof. Lawler: Sorry; I’m just trying to be clear. Is the research that you’re asking me about the research that you cited?

Senator ROBERTS: No, I haven’t cited anything. To your knowledge, has the health testing on aluminium build-up in our children’s bodies been done using water-soluble aluminium salts, which are not used in vaccine
products, or has the research been done using the actual aluminium found in vaccine products, aluminium hydroxide and aluminium phosphate Prof. Lawler: I’m sorry; I don’t know the research that you’re specifically referring to.

Senator ROBERTS: Okay. I’ll send you some papers. Is the type of aluminium in vaccine products bioresistant? Does it ever leave the bodies of our children?

Prof. Lawler: Again, there are a number of very specific and very technical questions that you’re asking us. For the purposes of answering them, as I’ve previously indicated, we’re very happy to take these questions—

Senator ROBERTS: That’s fine. I’ve got nothing against taking them on notice.

Prof. Lawler: Okay. I would like to provide you with as fulsome a response as possible.

Senator ROBERTS: Thank you. Are repeated doses of low concentrations of aluminium adjuvant in a vaccine product more harmful than a single large dose? A related question: how many vaccine products
containing aluminium hydroxide and aluminium phosphate has the TGA authorised for administration to children? You’ll have to take that on notice.

Prof. Lawler: I certainly will have to take that on notice.

Senator ROBERTS: I only had a concern about the one I objected to. I have no concern about the rest at all. I appreciate that it’s a better answer. Individual vaccine products have been safety tested. Has any safety testing been done on multiple, concurrent administration of vaccine products to babies under six months, with special attention to multiple administration of low dose aluminium adjuvants?

Prof. Lawler: Professor Langham can add to this response. There has been not only significant research undertaken with respect to the administration of vaccines but there is significant real-world evidence over decades on the safety of the administration of the vaccines that we approve.

Prof. Langham: I have nothing further to add on that. As you’re aware, we have a number of avenues whereby safety signals from all registered products in Australia are overseen from a pharmacovigilance
perspective, as Dr Larter has already mentioned. We work closely with other global regulators and also with other research that’s published. As Professor Lawler has said, with the vast body of information that exists about these vaccines and their use in children, there have been no signals.

Senator ROBERTS: So you can’t answer the question as to whether or not—

Prof. Langham: I think I did answer the question.

Senator Gallagher: Yes. I think that’s definitely an answer.

Senator ROBERTS: I’ll ask it again. Has any safety testing been done on multiple concurrent administration of vaccine products to babies under six months, with special attention to multiple administration of low-dose
aluminium adjuvants? Can you tell me if multiple injections have a different effect from one or two injections?

Prof. Langham: The evidence that exists from a safety perspective is not only the clinical trial data that we receive upon registration but also the ongoing evidence from a real-world perspective of the use of these vaccines in those multiple dose formulations in many millions of children around the world.

Prof. Lawler: For many years.

Senator ROBERTS: I have a last question. Are aluminium adjuvants causing the spectrum of neurological conditions that are commonly called autism?

Prof. Lawler: I’m not aware of any accepted evidence that that is the case.

Senator ROBERTS: Minister, you may sigh—

Senator Gallagher: Do you know why I sigh, Senator Roberts? It’s because I have a child with autism, and I have vaccinated children, and I find it offensive.

Senator ROBERTS: Well, I find it offensive to not respond to a constituent, and I’m responding to constituents. That’s my job. They pay me.

Senator Gallagher: Well, I’ve had enough.

Senator ROBERTS: Professor Lawler, have you heard of these papers? I think this will be my last question, Chair.

CHAIR: Yes, it will be.

Senator ROBERTS: I’ve mentioned one by Dr Karla Lehmann from 2024 titled ‘Suspected Causes of the Specific Intolerance Profile of Spike-Based Covid-19 Vaccines’ in the European Society of Medicine. There’s one
from 2022 by El-Arif G et al called ‘Angiotensin II Type I Receptor (AT1R): The Gate towards COVID-19 – Associated Diseases’ published in Molecules. In 2023 Fajloun and Sabatier published ‘The Unsuspected Role of the Renin-Angiotensin System (RAS): Could its Dysregulation be at the Root of All Non-Genetic Human Diseases?’ in Bentham Science. In 2023 Parry, P et al wrote, ‘”Spikeopathy”: COVID-19 Spike Protein Is
Pathogenic, from Both Virus and Vaccine mRNA’ in Biomedicines (Journal). The last one is from Pelumbo, Avila and Naftolin in 2016 called ‘The Ovarian Renin-Angiotensin System (OVRAS): A Major Factor in Ovarian Function and Disease’ in PubMed by the National Institute of Health, the National Library of Medicine USA.

Prof. Lawler: I’d be very happy to receive those studies—I’ll speak on behalf of Professor Langham if she doesn’t mind. I would say that there is a very well established understanding of the importance of the renin-angiotensin-aldosterone system in a number of various elements of regulation of human function. I think it is well recognised that they are impacted by the COVID disease itself.

Senator ROBERTS: What part of the COVID disease?

Prof. Lawler: It will be very useful for us to review those articles so that we can be sure that they are reflective of the impact of COVID not, as suggested, an impact of the vaccine.

Senator ROBERTS: Good. Thank you very much. Would you like the references sent as paper copies, as attachments or by links?

Prof. Lawler: At your pleasure.

Senator Gallagher: Carrier pigeon.

Senator ROBERTS: Chair, I’ll be putting forward a number of questions on notice on the spike protein.